Is NASDAQ:ARCT suited for growth investing?

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) is suited for growth investing. Investors should of course do their own research, but we spotted ARCTURUS THERAPEUTICS HOLDIN showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Some of the growth metrics of NASDAQ:ARCT highlighted

• ARCTURUS THERAPEUTICS HOLDIN has achieved an impressive Return on Equity (ROE) of 35.45%, showcasing its ability to generate favorable returns for shareholders.
• ARCTURUS THERAPEUTICS HOLDIN has a strong history of beating EPS estimates 3 times in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
• With impressive 1-year revenue growth of 475.0%, ARCTURUS THERAPEUTICS HOLDIN showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
• ARCTURUS THERAPEUTICS HOLDIN has achieved significant quarter-to-quarter (Q2Q) revenue growth of 237.0%, signaling its ability to capture market opportunities and drive top-line expansion. This growth underscores the company's effective execution and its potential for continued success.
• With a favorable trend in its operating margin over the past year, ARCTURUS THERAPEUTICS HOLDIN demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
• ARCTURUS THERAPEUTICS HOLDIN has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
• ARCTURUS THERAPEUTICS HOLDIN has shown positive momentum in its earnings per share (EPS) on a quarter-to-quarter (Q2Q) basis, with a 54.14% increase. This reflects the company's successful execution of its business strategies and its commitment to delivering improved financial results.
• The average next Quarter EPS Estimate for ARCTURUS THERAPEUTICS HOLDIN has experienced a 16.89% change in the last 3 months, reflecting evolving expectations by analysts regarding the company's EPS performance.
• The quarterly earnings of ARCTURUS THERAPEUTICS HOLDIN have shown a 54.14% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• accelerating EPS growth for ARCTURUS THERAPEUTICS HOLDIN: the current Q2Q growth of 54.14% exceeds the previous year Q2Q growth of 35.12%.

What is the full fundamental picture of NASDAQ:ARCT telling us.

ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

We assign a fundamental rating of 6 out of 10 to ARCT. ARCT was compared to 598 industry peers in the Biotechnology industry. ARCT has an excellent financial health rating, but there are some minor concerns on its profitability. ARCT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!

Our latest full fundamental report of ARCT contains the most current fundamental analsysis.

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.